Valuation, from the filing
| Public float | $3.23B | Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-30 |
|---|---|---|
| Float per share | $130.62 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
| Float / net income | 4405.8× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / revenue | 1.4× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / equity | 1.5× | A lower bound on the multiple, because affiliate holdings are excluded. |
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.
Valuation over time
4405.8× earnings today, against a median of 46.7× across 6 years on record. Above its own history.
| Float measured | Public float | Float / net income | |
|---|---|---|---|
| 2025-06-30 | $3.23B | 4405.8× | |
| 2020-06-30 | $3.31B | 38.1× | |
| 2019-06-28 | $4.84B | 47.9× | |
| 2018-06-30 | $5.58B | 193.6× | |
| 2017-06-30 | $3.13B | 45.6× | |
| 2016-06-30 | $1.64B | 26.1× |
Each float is paired with the fiscal year the filing that stated it covers. Only years where the company reported positive net income appear, because a multiple against a loss is not a multiple.
How this compares in its industry
Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
| Measure | Reported | Percentile | |
|---|---|---|---|
| Effective tax rate | 55.9% | 100th | |
| Revenue YoY growth | -6.3% | 15th | |
| Gross margin | 36.8% | 17th | |
| R&D / revenue | 3.9% | 20th | |
| SBC / revenue | 2.5% | 28th | |
| Net margin | 0.0% | 71th | |
| Operating margin | 1.9% | 70th | |
| FCF margin | 4.1% | 70th | |
| Current ratio | 2.39x | 41th | |
| CapEx / revenue | 3.9% | 54th | |
| Long-term debt / equity | 0.60x | 53th |
ICU MEDICAL INC/DE (ICUI) reported revenue of $2.16B for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from ICU MEDICAL INC/DE’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.
Income
| Metric | 2026-06-30 |
|---|---|
| Revenue | $2.16B |
| Cost of revenue | Unavailable |
| Gross profit | $845.14M |
| Operating income | $72.06M |
| Net income | Unavailable |
| Research & development | $86.32M |
| Weighted-average diluted shares | Unavailable |
| Pretax income | Unavailable |
| Income tax expense | -$30.96M |
| Diluted EPS | Unavailable |
| Selling, general & administrative | $615.07M |
| General & administrative | Unavailable |
| Selling & marketing | Unavailable |
Balance
| Metric | 2026-06-30 |
|---|---|
| Cash & equivalents | Unavailable |
| Total assets | $3.97B |
| Current assets | $1.21B |
| Total liabilities | Unavailable |
| Current liabilities | $498.36M |
| Total equity incl. NCI | $2.15B |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | $607.42M |
| Accounts receivable | $183.53M |
| Goodwill | $1.48B |
| Long-term debt | $1.21B |
| Accounts payable | $149.16M |
Cash flow
| Metric | 2026-06-30 |
|---|---|
| Operating cash flow | $236.37M |
| Capital expenditures | $83.54M |
| Investing cash flow | -$79.76M |
| Financing cash flow | -$154.53M |
| Net change in cash | -$1.73M |
| Stock-based compensation | $55.00M |
| Common dividends paid | Unavailable |
| Common share repurchases | Unavailable |
| Depreciation & amortization | $201.27M |
Derived
| Metric | 2026-06-30 |
|---|---|
| Free cash flow | $152.83M |
| Gross margin | 39.1% |
| Operating margin | 3.3% |
| FCF margin | 7.1% |
| SBC / revenue | 2.5% |
| Current ratio | 2.43x |
| Revenue YoY growth | -9.0% |
| Net margin | Unavailable |
| R&D / revenue | 4.0% |
| CapEx / revenue | 3.9% |
| Long-term debt / equity | 0.56x |
| Effective tax rate | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ICUI in the interactive workspace to inspect any figure back to its filing.
Source filings
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.